Septic shock due to Candida famata (Debaryomyces hansenii) candidemia in an ICU immunocompetent trauma-patient

Journal of Infection and Public Health

Volumn 12, Issue 4, 2019, Pages 594-597

  Karapetsa, Maria ^a   Tsolaki, Vasiliki ^a   Arabatzis, Michael ^b,c   Petinaki, Efi ^d   Velegraki, Aristea ^b   Zakynthinos, Epaminondas ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

Author keywords

Candida famata; Debaryomyces hansenii; Intensive Care Unit; Multi trauma patient; Septic shock

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIINFECTIVE AGENT; COLISTIN; DAPTOMYCIN; DNA 26S; METRONIDAZOLE; TIGECYCLINE; ANTIFUNGAL AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL EMBOLIZATION; CANDIDEMIA; CASE REPORT; CLINICAL ARTICLE; DEBARYOMYCES HANSENII; DEBRIDEMENT; ERYTHROCYTE; FRACTURE EXTERNAL FIXATION; FUNGEMIA; HEMATOTHORAX; HEMORRHAGIC SHOCK; HOSPITALIZATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INTERNAL ILIAC ARTERY; LENGTH OF STAY; LOADING DRUG DOSE; LUNG CONTUSION; MALE; PRIORITY JOURNAL; RISK FACTOR; SEPTIC SHOCK; SPLENECTOMY; SURGICAL INFECTION; TOTAL PARENTERAL NUTRITION; TRAUMATIC BRAIN INJURY; URINARY TRACT INFECTION; COMPLICATION; DEBARYOMYCES; GENETICS; IMMUNOCOMPETENCE; INJURY; INTENSIVE CARE; MICROBIOLOGY; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDEMIA; CRITICAL CARE; DEBAROMYCES; HUMANS; IMMUNOCOMPETENCE; INTENSIVE CARE UNITS; MALE; RISK FACTORS; SHOCK, SEPTIC; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 85059569356     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2018.12.015     Document Type: Article

References (17)

1. Arendrup, M.C., Cuenca-Estrella, M., Lass-Flörl, C., Hope, W., EUCAST-AFST, EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 18 (2012), 246–247, 10.1111/j.1469-0691.
2. Beyda, N., Chuang, S., Alam, M., Shah, D.N., Ng, T.M., McCaskey, L., et al. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother 68 (2013), 438–443, 10.1093/jac/dks388.
3. Quindos, G., Cabrera, F., Arilla, M., Burgos, A., Ortiz-Vigon, R., Canon, J.L., et al. Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole. CID 18 (1994), 658–660.
4. Carrega, G., Riccio, G., Santoriello, L., Pasqualini, M., Pellicci, R., Candida famata fungemia in a surgical patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 16 (1997), 698–699.
5. Krcmery, V., Kunova, A., Candida famata fungemia in a cancer patient: case report. J Chemother 12 (2000), 189–190, 10.1179/joc.2000.12.2.189.
6. Wagner, D., Sander, A., Bertz, H., Finke, J., Kern, W.V., Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 33 (2005), 397–400, 10.1007/s15010-005-5082-4.
7. Gupta, A., Mi, H., Wroe, C., Jaques, B., Talbot, D., Fatal Candida famata peritonitis complicating sclerosing peritonitis in a peritoneal dialysis patient. Nephrol Dial Transplant 21 (2006), 2036–2037, 10.1093/ndt/gfl040.
8. Struck, M., Stiller, D., Corterier, C., Reichelt, B., Steen, M., Fulminant undetected Candida sepsis after an apparently survivable burn injury. J Burn Care Res 30 (2009), 894–897, 10.1097/BCR.0b013e3181b48794.
9. Turunc, T., Demiroglu, Y.Z., Aliskan, H., Colakoglu, S., Arslan, H., [Retrospective evaluation of the cases with Candida famata fungemia in a burn unit]. Mikrobiyol Bul 43:1 (2009), 71–76.
10. Desnos-Ollivier, M., Ragon, M., Robert, V., Raoux, D., Gantier, J.C., Dromer, F., Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol 46 (2008), 3237–3242, 10.1128/JCM.01451-08.
11. Schuster, M.G., Meibohm, A., Lloyd, L., Strom, B., Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. J Infect 66 (2013), 278–284, 10.1016/j.jinf.2012.11.002.
12. Chow, J.K., Golan, Y., Ruthazer, R., Karchmer, A.W., Carmeli, Y., Lichtenberg, D.A., et al. Risk factors for albicans and non albicans candidemia in the intensive care unit. Crit Care Med 36 (2008), 1993–1998, 10.1097/CCM.0b013e31816fc4cd.
13. Blumberg, H.M., Jarvis, W.R., Soucie, J.M., Edwards, J.E., Patterson, J.E., Pfaller, M.A., Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33 (2001), 177–186, 10.1086/321811.
14. Frazier, W.J., Hall, W.M., Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin North Am 55 (2008), 647–669, 10.1016/j.pcl.2008.02.009.
15. Marik, E.P., Flemmer, M., The immune response to surgery and trauma: implications for treatment. J Trauma Acute Care Surg 73 (2012), 801–808, 10.1097/TA.0b013e318265cf87.
16. Castanheira, M., Woosley, L.N., Diekema, D.J., Jones, R.N., Pfaller, M.A., Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by Vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization—time of flight mass spectrometry in two global antifungal surveillance programs. J Clin Microbiol 51 (2013), 117–124, 10.1128/JCM. 01686-12.
17. Hendrickx, Marijke, MALDI-TOF MS and filamentous fungal identification: a success story?. Curr Fungal Infect Rep 11 (2017), 60–65, 10.1007/s12281-017-0277-6.